Pfizer & Medivation sign $725 million Dimebon deal
This article was originally published in Scrip
Executive Summary
Pfizerand Medivationhave signed an agreement to develop and commercialise the smaller company's lead product Dimebon for the treatment of Alzheimer's disease and Huntington's disease.